BVS:NSD-Bioventus Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 11.17

Change

+0.26 (+2.38)%

Market Cap

USD 0.62B

Volume

0.45M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-13 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-1.15 (-1.64%)

USD 27.85B
PODD Insulet Corporation

+1.65 (+0.71%)

USD 16.40B
BRKR Bruker Corporation

-0.25 (-0.38%)

USD 9.94B
MASI Masimo Corporation

+1.04 (+0.91%)

USD 6.03B
TMDX TransMedics Group Inc

+4.87 (+3.22%)

USD 5.04B
PRCT Procept Biorobotics Corp

-2.18 (-2.66%)

USD 4.00B
AXNX Axonics Modulation Technologie..

-0.12 (-0.17%)

USD 3.52B
QDEL Quidel Corporation

+0.36 (+0.78%)

USD 3.06B
TNDM Tandem Diabetes Care Inc

+0.36 (+0.84%)

USD 2.88B
LIVN LivaNova PLC

+2.21 (+4.53%)

USD 2.64B

ETFs Containing BVS

FKU First Trust United Kingdo.. 2.53 % 0.80 %

+0.07 (+0.82%)

USD 0.07B
FKU:LSE First Trust United Kingdo.. 2.50 % 0.00 %

+31.50 (+0.82%)

USD 6.70M
FKUD:LSE First Trust United Kingdo.. 2.50 % 0.00 %

+29.50 (+0.82%)

USD 2.32M
CUKS:LSE iShares VII PLC - iShares.. 1.30 % 0.00 %

+130.00 (+0.82%)

USD 0.18B
XXSC:LSE db x-trackers MSCI Europe.. 0.49 % 0.00 %

+40.75 (+0.82%)

USD 1.94B
FNDC Schwab Fundamental Intern.. 0.00 % 0.39 %

-0.12 (0.82%)

USD 3.25B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 111.95% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 111.95% 95% A 95% A
Trailing 12 Months  
Capital Gain 266.23% 97% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 266.23% 97% N/A 98% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.87% 64% D 68% D+
Dividend Return 10.87% 64% D 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 101.50% 29% F 17% F
Risk Adjusted Return 10.71% 67% D+ 48% F
Market Capitalization 0.62B 75% C 65% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector